Known targets — ChEMBL curated mechanism
ABL1BRAFDDR2EPHA2FGFR1FGFR2FLT1FLT4FRKKDRKITMAPK11NTRK1PDGFRAPDGFRBRAF1RETTEK
The experimentally established mechanism targets of Regorafenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 known ✓ | P04049 | 12/20 | 1.00 |
| ▸ | BRAF known ✓ | P15056 | 7/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 6/20 | 1.00 |
| ▸ | RET known ✓ | P07949 | 3/20 | 1.00 |
| ▸ | ABL1 known ✓ | P00519 | 2/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 1.00 |
| ▸ | FGFR1 known ✓ | P11362 | 2/20 | 1.00 |
| ▸ | PDGFRA known ✓ | P16234 | 2/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 2/20 | 1.00 |
| ▸ | EPHA2 known ✓ | P29317 | 2/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 1.00 |
| ▸ | TEK known ✓ | Q02763 | 2/20 | 1.00 |
| ▸ | MAPK11 known ✓ | Q15759 | 2/20 | 1.00 |
| ▸ | DDR2 known ✓ | Q16832 | 2/20 | 1.00 |
| ▸ | NTRK1 known ✓ | P04629 | 1/20 | 0.83 |
| ▸ | FGFR2 known ✓ | P21802 | 1/20 | 0.83 |
| ▸ | FRK known ✓ | P42685 | 1/20 | 0.83 |
| ▸ | RIPK2 | O43353 | 3/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Regorafenib SCHEMBL29349808 | 1.00 | RAF1 (1.00) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL432230 | 1.00 | RAF1 (1.00) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL29496390 | 0.99 | RAF1 (0.98) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL2554008 | 0.99 | RAF1 (0.98) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL29555444 | 0.99 | RAF1 (0.98) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL2555101 | 0.99 | RAF1 (0.98) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL2552684 | 0.97 | RAF1 (0.93) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL30433607 | 0.94 | RAF1 (0.89) | RAF1BRAFKDRRETRIPK2 | |
| SCHEMBL5086313 | 0.93 | RAF1 (0.87) | RAF1BRAFKDRRETRIPK2 | |
| SCHEMBL22627130 | 0.92 | RAF1 (0.85) | RAF1BRAFKDRRETRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119667011-A | Method for measuring compound | 四川科伦药物研究院有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-118139621-A | Method for amplifying erythroid precursor cells or erythroblasts and application thereof | 北京大学 | 2024-06-04 | — | — | CN | claimed |
| WO-2024105225-A1 | SYNERGISTIC COMBINATIONS OF A SIGMA RECEPTOR 1 (S1R) ANTAGONIST AND A SOLUBLE EPOXIDE HYDROLASE INHIBITOR (SEHI) AND THEIR USE IN THE TREATMENT OF PAIN | UNIVERSITAT DE BARCELONA (ES) | 2024-05-23 | — | — | WO | claimed |
| WO-2023051685-A1 | METHOD FOR AMPLIFYING ERYTHROID PROGENITORS OR ERYTHROBLASTS, AND APPLICATION THEREOF | 北京大学 | 2023-04-06 | — | — | WO | claimed |
| US-12636250-B2 | Microneedle array patches (MAPs), systems, and methods for manufacturing and using same | TERRESTRIAL BIO, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260139051-A1 | COMBINATION THERAPIES USING MOLECULES BINDING TO TCR | MARENGO THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12630864-B2 | Methods of nucleic acid sample preparation | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4724500-A2 | MULTISPECIFIC MOLECULES BINDING TO TCR AND USES THEREOF | Marengo Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260022173-A1 | ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF | MARENGO THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20260007869-A1 | MICRONEEDLE ARRAY PATCHES (MAPS), SYSTEMS, AND METHODS FOR MANUFACTURING AND USING SAME | VAXESS TECHNOLOGIES, INC. (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250382365-A1 | ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF | NOVARTIS AG (CH) | 2025-12-18 | — | — | US | disclosed |
| US-20250376715-A1 | METHODS OF PREPARING NUCLEIC ACIDS FOR SEQUENCING | THE GENERAL HOSPITAL CORPORATION (US) | 2025-12-11 | — | — | US | disclosed |
| US-11312783-B2 | Antibody molecules to CD73 and uses thereof | NOVARTIS AG (CH) | 2022-04-26 | — | — | US | disclosed |
| US-11312766-B2 | Antibodies against growth differentiation factor 15 and uses thereof | NOVARTIS AG (CH) | 2022-04-26 | — | — | US | disclosed |
| WO-2022052913-A1 | COMPOSITIONS AND METHODS FOR T CELL ENGINEERING | GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. (CN) | 2022-03-17 | — | — | WO | disclosed |
| EP-3370768-B9 | ANTIBODIES SPECIFICALLY BINDING PD-1 AND THEIR USES | JANSSEN BIOTECH INC (US) | 2022-03-16 | — | — | EP | disclosed |
| WO-2022047046-A1 | METHODS OF DETECTING TRBC1 OR TRBC2 | MARENGO THERAPEUTICS, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| US-20220064297-A1 | ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF | MARENGO THERAPEUTICS, INC. | 2022-03-03 | — | — | US | disclosed |
| WO-2022046920-A2 | MULTIFUNCTIONAL MOLECULES THAT BIND TO CALRETICULIN AND USES THEREOF | MARENGO THERAPEUTICS, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| US-11230589-B2 | Fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230589-B2 | Fusion molecules and uses thereof | RPS27A, CD2BP2, FGB | RAF1 2779/4885BRAF 3001/4885KDR 1552/4885 |
| US-12630864-B2 | Methods of nucleic acid sample preparation | POLL, DNMT3A, POLM | RAF1 1535/4885BRAF 585/4885KDR 105/4885 |
| US-20260022173-A1 | ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF | IGLV6-57, IGSF11, VSIR | RAF1 2429/4885BRAF 3066/4885KDR 206/4885 |
| US-12636250-B2 | Microneedle array patches (MAPs), systems, and methods for manufacturing and using same | GLP1R, NPY1R, NPY4R | RAF1 1315/4885BRAF 1599/4885KDR 482/4885 |
| US-20250382365-A1 | ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF | CD47, CD2, CD58 | RAF1 4667/4885BRAF 4516/4885KDR 2421/4885 |
| US-20260139051-A1 | COMBINATION THERAPIES USING MOLECULES BINDING TO TCR | CD2, CD4, CD47 | RAF1 2678/4885BRAF 2351/4885KDR 1102/4885 |
| US-11312783-B2 | Antibody molecules to CD73 and uses thereof | NT5E, ENTPD5, ENTPD1 | RAF1 4617/4885BRAF 3972/4885KDR 1439/4885 |
| US-20260007869-A1 | MICRONEEDLE ARRAY PATCHES (MAPS), SYSTEMS, AND METHODS FOR MANUFACTURING AND USING SAME | IAPP, NPY1R, NPY2R | RAF1 850/4885BRAF 542/4885KDR 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.